Brian Slomovitz
GOG Foundation · Icahn School of Medicine at Mount Sinai · GOG
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brian Slomovitz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07672782 · Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaGOG Foundation · not yet recruiting · Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva · study chair
- Ph3NCT07044336 · Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)AstraZeneca · recruiting · Endometrial Cancer, Malignant Solid Tumour · principal investigator
- Ph2NCT03673124 · Ribociclib and Letrozole Treatment in Ovarian CancerGynecologic Oncology Group · active not recruiting · Low Grade Serous Carcinoma · study chair
- N/ANCT02834988 · Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial CancerUniversity of Miami · completed · Endometrial Cancer · principal investigator
- Ph2NCT02228681 · Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial CancerGOG Foundation · completed · Advanced, Persistent, or Recurrent Endometrial Cancer · study chair
- N/ANCT01500512 · Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node DissectionGynecologic Oncology Group · unknown · Stage I Vulvar Cancer, Stage II Vulvar Cancer, Stage III Vulvar Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT01500512
- Gynecologic Oncology GroupU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 1985 to 2013Named on NCT01500512
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:57 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.N Engl J Med · 2023744 citationsRCR 66.0
- Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.J Clin Oncol · 2015245 citationsRCR 7.6
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.Lancet Oncol · 2019210 citationsRCR 8.0
- 205 citationsRCR 13.3
- 186 citationsRCR 4.3
- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.N Engl J Med · 2024164 citationsRCR 24.0
- 118 citationsRCR 13.3
- A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.Clin Cancer Res · 2012111 citationsRCR 2.6
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.Clin Cancer Res · 2020111 citationsRCR 4.7
- Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.Lancet Oncol · 2020104 citationsRCR 3.8